1. Generics Bulletin
  2. >>Business

Hyloris Adds Aguettant Deals For Maxigesic IV In Europe

Partner AFT Signs Licensing Agreements In Eight European Markets

 
• By Dave Wallace

Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.

Europe Deal Handshake
Deals have been signed covering a further eight European markets • Source: Shutterstock

Belgian value added medicines specialist Hyloris Pharmaceuticals has secured licensing deals with Aguettant for its Maxigesic IV (paracetamol/ibuprofen) value added medicine in a further eight European markets through its partner, New Zealand’s AFT Pharmaceuticals.

Talking to Generics Bulletin last year, Hyloris CEO Stijn Van Rompay described Maxigesic IV – which is delivered through intravenous infusion – as “one of the strongest non-opioid IV pain products that will be made available globally,” insisting that it “represents great added value given the high need for first-line pain management therapy alternatives

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.